A recombinant rabies vaccine expressing the trimeric form of the glycoprotein confers enhanced immunogenicity and protection in outbred mice.

[1]  S. Addya,et al.  Immune Clearance of Attenuated Rabies Virus Results in Neuronal Survival with Altered Gene Expression , 2012, PLoS pathogens.

[2]  N. Johnson,et al.  Developments in rabies vaccines , 2012, Clinical and experimental immunology.

[3]  K. Karlsson,et al.  Matrix-M™ Adjuvant Induces Local Recruitment, Activation and Maturation of Central Immune Cells in Absence of Antigen , 2012, PloS one.

[4]  R. Cox,et al.  T-helper 1 cells elicited by H5N1 vaccination predict seroprotection. , 2012, The Journal of infectious diseases.

[5]  T. Kuiken,et al.  In Vitro and In Vivo Isolation and Characterization of Duvenhage Virus , 2012, PLoS pathogens.

[6]  Who Publication.  Rubella vaccines: WHO position paper--recommendations. , 2011 .

[7]  S. Xiao,et al.  Construction and immunogenicity of a recombinant pseudotype baculovirus expressing the glycoprotein of rabies virus in mice , 2011, Archives of Virology.

[8]  J. Mascola,et al.  Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates , 2010, The Journal of experimental medicine.

[9]  Albert D. M. E. Osterhaus,et al.  Recombinant Soluble, Multimeric HA and NA Exhibit Distinctive Types of Protection against Pandemic Swine-Origin 2009 A(H1N1) Influenza Virus Infection in Ferrets , 2010, Journal of Virology.

[10]  R. Bhatnagar,et al.  Rabies DNA vaccine encoding lysosome‐targeted glycoprotein supplemented with Emulsigen‐D confers complete protection in preexposure and postexposure studies in BALB/c mice , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  Rabies vaccines: WHO position paper--recommendations. , 2010, Vaccine.

[12]  N. Van Rooijen,et al.  Vesicular Stomatitis Virus Genomic RNA Persists In Vivo in the Absence of Viral Replication , 2009, Journal of Virology.

[13]  M. Schnell,et al.  A single immunization with a recombinant canine adenovirus expressing the rabies virus G protein confers protective immunity against rabies in mice. , 2006, Virology.

[14]  R. Cox,et al.  Pandemic influenza vaccine development: time is of the essence , 2006, Expert review of vaccines.

[15]  J. Mascola,et al.  Characterization of Antibody Responses Elicited by Human Immunodeficiency Virus Type 1 Primary Isolate Trimeric and Monomeric Envelope Glycoproteins in Selected Adjuvants , 2006, Journal of Virology.

[16]  T. Lembo.  WHO Expert Consultation on rabies. , 2010, World Health Organization technical report series.

[17]  Dinesh Kumar Yadav,et al.  High level expression of surface glycoprotein of rabies virus in tobacco leaves and its immunoprotective activity in mice , 2005, Journal of Biotechnology.

[18]  P. Wakeley,et al.  Development of a Real-Time, TaqMan Reverse Transcription-PCR Assay for Detection and Differentiation of Lyssavirus Genotypes 1, 5, and 6 , 2005, Journal of Clinical Microbiology.

[19]  S. Nutt,et al.  Early appearance of germinal center–derived memory B cells and plasma cells in blood after primary immunization , 2005, The Journal of experimental medicine.

[20]  G. Kärber,et al.  Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche , 1931, Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie.

[21]  John L. Sullivan,et al.  Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus , 2003, Nature.

[22]  M. Schnell,et al.  New approaches to the prevention and eradication of rabies , 2003, Expert review of vaccines.

[23]  J. Sodroski,et al.  Improved Elicitation of Neutralizing Antibodies against Primary Human Immunodeficiency Viruses by Soluble Stabilized Envelope Glycoprotein Trimers , 2001, Journal of Virology.

[24]  M. Aubert,et al.  Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody. , 1998, Journal of immunological methods.

[25]  T. Hulland.  A Biographical History of Veterinary Pathology , 1997 .

[26]  R. Ahmed,et al.  Bone marrow is a major site of long-term antibody production after acute viral infection , 1995, Journal of virology.

[27]  C. Rupprecht,et al.  Oral vaccination of racoons (Procyon lotor) with baculovirus-expressed rabies virus glycoprotein. , 1993, Vaccine.

[28]  R. Ruigrok,et al.  Rabies virus glycoprotein is a trimer , 1992, Virology.

[29]  K. Takehara,et al.  Immunogenic and protective properties of rabies virus glycoprotein expressed by baculovirus vectors. , 1989, Virology.

[30]  A. Osterhaus,et al.  Characterization of a new virus-neutralizing epitope that denotes a sequential determinant on the rabies virus glycoprotein. , 1989, The Journal of general virology.

[31]  T. Wiktor,et al.  Antigenic sites on the CVS rabies virus glycoprotein: analysis with monoclonal antibodies. , 1983, The Journal of general virology.